KVUE - Comprehensive Filing Intelligence

FY 2025•10-K•Filed Feb 20, 2026
5.0/10
Filing Health:CAUTION

Notable concerns that warrant closer review

Executive Summary

Significant unestimatable litigation exposure related to acetaminophen and alleged links to neurodevelopmental disorders.. Net sales decreased by 2.1% year-over-year. See detailed pass outputs for comprehensive analysis.

Top Concerns

  • !Overall revenue declined by 2.1% due to softer volumes, particularly in the US and China, though pricing initiatives provided some offset.
  • !Gross margin improved slightly by 10 basis points due to supply chain optimizations, but was pressured by input cost inflation and tariffs.
  • !Essential Health segment showed resilience with modest operating income growth, while Skin Health and Beauty faced significant margin pressure.
  • !Significant asset impairments in prior periods ($578 million in FY2024) affect earnings comparability.
  • !Changes in accounting policy for GILTI from deferred to period cost approach.

Top Positives

  • +Operating income saw a substantial increase, primarily driven by a significant reduction in impairment charges from the prior year.
  • +Operating cash flow improved by 24.2% driven by favorable working capital movements, indicating strong cash generation quality.

Analysis Dimensions

Our 5-pass AI analysis examines this filing across multiple dimensions. Each dimension score is derived from direct analysis of SEC filing text.

Narrative Intelligence

7.0/10

Management tone is balanced with focus on gains from supply chain optimization initiatives.

Full analysis includes: tone changes vs prior quarter, margin driver breakdown, forward guidance analysis, strategic priorities.

Accounting Quality

7.0/10

Earnings quality shows moderate accounting practices.

Full analysis includes: reserve and allowance changes, non-recurring item analysis, stock-based compensation impact, disclosure concerns.

Hidden Liabilities

Off-balance sheet risk is moderate.

Full analysis includes: cloud and purchase commitments, VIE/SPE exposure, covenant compliance status, refinancing risk assessment.

Risk Landscape

4.0/10

Overall risk profile shows proposed transaction risks as primary concern.

Full analysis includes: 8 risk categories with severity, new vs escalated risks, management response assessment, risk trend analysis.

Segment Performance

5.0/10

Segment health analysis shows Essential Health as strongest performer while Skin Health and Beauty lags.

Full analysis includes: segment-by-segment revenue breakdown, geographic concentration risk, customer concentration analysis, segment margin trends.

Related Research

Analysis

KVUE 10-K Analysis: Why Kenvue's Earnings Recovery Is 97% Non-Operational